These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 12231546

  • 1. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL.
    Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
    [Abstract] [Full Text] [Related]

  • 2. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL.
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
    [Abstract] [Full Text] [Related]

  • 3. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL.
    Clin Cancer Res; 2007 Dec 01; 13(23):7217-23. PubMed ID: 18056203
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR, Gerberich JL, Nowotnik DP, Howell SB.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [Abstract] [Full Text] [Related]

  • 6. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, Pearson AD, Boddy AV, Newell DR, Tilby MJ.
    Clin Cancer Res; 2001 Aug 01; 7(8):2205-12. PubMed ID: 11489793
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.
    Cancer Chemother Pharmacol; 2002 Mar 01; 49(3):201-10. PubMed ID: 11935212
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T.
    Cancer Chemother Pharmacol; 2007 Apr 01; 59(5):575-80. PubMed ID: 16912889
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS, Kanekal S, Lin XR, Leung TW, Chan AT, Yeo W, Yu S, Chak K, Leavitt R, Johnson P.
    Cancer; 2001 Jun 15; 91(12):2369-77. PubMed ID: 11413527
    [Abstract] [Full Text] [Related]

  • 14. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
    Ognio E, Chiavarina B, Caviglioli G, Lapide M, Viale M.
    Arch Toxicol; 2004 Oct 15; 78(10):584-8. PubMed ID: 15150682
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.
    Chem Biol Interact; 2004 Jun 30; 148(1-2):37-48. PubMed ID: 15223355
    [Abstract] [Full Text] [Related]

  • 16. Influence of a novel platinum compound--cis-dichloro (dimethylsulphoxide) (1-beta-D-rybofuranosyl-1,2,4-triazolo-3-arboxyamide) platinum (II)--"Pt-rib-1"--on cell cycle and apoptosis in ClS91 and B16 mouse melanoma in vitro.
    Drewa T, Olszewska-Słonina D, Woźniak A, Styczyński J, Drewa G, Szłyk E, Lakomska I, Kobe J, Czajkowski R.
    Acta Pol Pharm; 2004 Jun 30; 61(1):39-44. PubMed ID: 15259856
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW, van der Born K, Erkelens CA, Hamelers IH, Peters GJ, Boven E, de Kroon AI.
    Anticancer Drugs; 2008 Aug 30; 19(7):721-7. PubMed ID: 18594214
    [Abstract] [Full Text] [Related]

  • 18. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
    Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA.
    Cancer Chemother Pharmacol; 1999 Aug 30; 43(1):1-7. PubMed ID: 9923534
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
    Deng C, Huang R, Lian L.
    Zhonghua Fu Chan Ke Za Zhi; 1996 Mar 30; 31(3):159-62. PubMed ID: 8758790
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
    Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh-hara T, Tsuruo T, Yamada Y.
    Cancer Res; 1996 Jun 15; 56(12):2809-14. PubMed ID: 8665518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.